Etaracizumab
- Generic Name
- Etaracizumab
- Drug Type
- Biotech
- CAS Number
- 892553-42-3
- Unique Ingredient Identifier
- 41W9MFI160
- Background
Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer
- Conditions
- Recurrent Renal Cell CancerRenal Cell CarcinomaStage III Renal Cell CancerStage IV Renal Cell Cancer
- Interventions
- Biological: bevacizumab
- First Posted Date
- 2008-05-28
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 5
- Registration Number
- NCT00684996
- Locations
- ๐บ๐ธ
University of California at Davis Cancer Center, Sacramento, California, United States
๐บ๐ธSWOG, Portland, Oregon, United States
๐บ๐ธFremont - Rideout Cancer Center, Marysville, California, United States
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
- First Posted Date
- 2006-02-01
- Last Posted Date
- 2008-05-29
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 17
- Registration Number
- NCT00284817
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2009-01-29
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00263783
- Locations
- ๐ซ๐ท
Institut Gustave Roussy, Villejuf, France
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 44
- Registration Number
- NCT00192517
- Locations
- ๐บ๐ธ
NorthEast Clinical Research Centers, Inc, Allentown, Pennsylvania, United States
๐บ๐ธSouth Bend Clinic, South Bend, Indiana, United States
๐บ๐ธDermatology Specialists, Vista, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.